Fierce Healthcare3d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
JD Supra5h
End of Semaglutide Shortage Means Big Changes for Prescribers and Compounders
On February 21, the FDA announced that the shortage of semaglutide injection products has been resolved. Semaglutide has appeared on the FDA’s ...
pharmaphorum12h
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
devdiscourse2h
Legal Battle Over Semaglutide Supply: Compounders vs FDA
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
The Ozempic shortage is over, a big threat to off-brand weight loss drug sellers
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, ...
FDA to spare compounders as Novo Nordisk’s Ozempic supply begins to improve
The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an ...
BioSpace3d
Illegal GLP-1 Ingredients ‘Flooding’ Into US: Report
Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...
STAT4d
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.